Wellmark Blue Cross & Blue Shield has decided to rescind a controversial proposal whereby hospitals in South Dakota would have been asked to report modifiers on claims to denote the use of drugs acquired under the 340B program by April 1.
Wellmark made the decision to reevaluate the proposed policy after receiving a joint-letter from the South Dakota Association of Healthcare Organizations (SDAHO) and Iowa Hospital Association (IHA), which outlined significant concerns from their members.
